Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
ABVC Biopharma Inc(ABVC)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for ABVC
10/08/2026: ABVC (1-star) has a low Upturn Star Rating. Not recommended to BUY.
ABVC Biopharma Inc is a clinical-stage biotechnology company focused on in-licensing and developing medical products across oncology, neurology, and ophthalmology. The company's main strength lies in its diverse pipeline and a lean operational model designed to leverage international research partnerships. Its primary growth story centers on achieving regulatory approval and commercializing assets like Vitargus and ABVC-1. Investors face significant risks, including clinical trial failure, limited financial resources, and intense competition from much larger, better-funded pharmaceutical firms. This stock is suitable for high-risk growth investors interested in the biotechnology sector who should closely monitor upcoming clinical trial outcomes and regulatory progress.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers high-risk/high-reward exposure to biotech R&D but lacks a consistent growth track record. |
| Momentum investor | Mixed fit | Momentum fits only during clinical milestone announcements or positive regulatory news cycles. |
| Value investor | Weak fit | Lack of earnings and significant cash burn make traditional value metrics inapplicable. |
| Dividend investor | Weak fit | The company does not pay a dividend and focuses entirely on funding clinical operations. |
| Low-risk investor | Weak fit | Clinical-stage biotech stocks are inherently highly volatile and carry substantial existential risk. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock is susceptible to large price swings based on clinical trial results and financing news. |
| Valuation risk | High | Valuation is speculative and highly sensitive to assumptions about future product success. |
| Competition risk (Large Pharma) | High | ABVC competes against well-funded incumbents with superior commercial infrastructure. |
| Business quality | Medium | The business model relies on external in-licensing rather than internal discovery, creating a unique execution risk profile. |
| Dividend income | Low / none | No income is generated for shareholders. |
| Execution risk | High | The complexity of managing clinical trials and regulatory pathways across borders is significant. |
Price Behavior
Steep Decline
The stock price has dropped sharply with strong downward pressure.
Highly Choppy
The stock has experienced frequent, large price swings that make its near-term movement less predictable.
Analysis of Past Performance
Type Stock | Historic Profit 98.47% | Avg. Invested days 19 | Today’s Advisory WEAK BUY |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 10/08/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 28.03M USD | Price to earnings Ratio - | 1Y Target Price 2.02 |
Price to earnings Ratio - | 1Y Target Price 2.02 | ||
Volume (30-day avg) 123.3K shares | Beta 0.51 | 52 Weeks Range 0.71 - 3.33 | Updated Date 10/08/2026 |
52 Weeks Range 0.71 - 3.33 | Updated Date 10/08/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.3 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Pharmaceutical Development | Clinical trial development of drug candidates for CNS and oncology indications. | Revenue is currently negligible; the company is investing in long-term potential drug approvals. |
| Licensing and Partnerships | Licensing intellectual property to global pharmaceutical manufacturers. | The company aims to monetize its IP through upfront payments and future royalty streams. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 32.91M | Price to Sales(TTM) 111.69 |
Enterprise Value 32.91M | Price to Sales(TTM) 111.69 | ||
Enterprise Value to Revenue 184.61 | Enterprise Value to EBITDA -1.9 | Shares Outstanding 26.69M | Shares Floating 21.10M |
Shares Outstanding 26.69M | Shares Floating 21.10M | ||
Percent Insiders 18.09 | Percent Institutions 4.08 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About ABVC Biopharma Inc
Exchange NASDAQ | Headquarters Fremont, CA, United States | ||
IPO Launch date 2017-10-11 | CEO & Interim CFO Dr. Uttam Yashwant Patil Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 16 | Website https://www.abvcpharma.com |
Full time employees 16 | Website https://www.abvcpharma.com | ||
ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus, which is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer; ABV-2001, an intraocular irrigation solution; ABV-2002, a corneal Storage Solution; and ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer. The company has a co-development agreement with Rgene Corporation and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.